BR112022014272A2 - Fator de crescimento derivado de mieloide para uso no tratamento ou prevenção de fibrose, hipertrofia ou insuficiência cardíaca - Google Patents
Fator de crescimento derivado de mieloide para uso no tratamento ou prevenção de fibrose, hipertrofia ou insuficiência cardíacaInfo
- Publication number
- BR112022014272A2 BR112022014272A2 BR112022014272A BR112022014272A BR112022014272A2 BR 112022014272 A2 BR112022014272 A2 BR 112022014272A2 BR 112022014272 A BR112022014272 A BR 112022014272A BR 112022014272 A BR112022014272 A BR 112022014272A BR 112022014272 A2 BR112022014272 A2 BR 112022014272A2
- Authority
- BR
- Brazil
- Prior art keywords
- treatment
- hypertrophy
- fibrosis
- heart failure
- myeloid
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Cardiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20153008 | 2020-01-21 | ||
| PCT/EP2021/051079 WO2021148411A1 (en) | 2020-01-21 | 2021-01-19 | Myeloid-derived growth factor for use in treating or preventing fibrosis, hypertrophy or heart failure |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022014272A2 true BR112022014272A2 (pt) | 2022-09-20 |
Family
ID=69187588
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022014272A BR112022014272A2 (pt) | 2020-01-21 | 2021-01-19 | Fator de crescimento derivado de mieloide para uso no tratamento ou prevenção de fibrose, hipertrofia ou insuficiência cardíaca |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230059560A1 (https=) |
| EP (1) | EP4093750A1 (https=) |
| JP (1) | JP7777532B2 (https=) |
| KR (1) | KR20220131262A (https=) |
| CN (1) | CN115698048A (https=) |
| AU (1) | AU2021211874A1 (https=) |
| BR (1) | BR112022014272A2 (https=) |
| CA (2) | CA3164500A1 (https=) |
| MX (1) | MX2022008727A (https=) |
| PH (1) | PH12022551792A1 (https=) |
| TW (1) | TW202142254A (https=) |
| WO (1) | WO2021148411A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11980654B2 (en) | 2020-09-22 | 2024-05-14 | Wisconsin Alumni Research Foundation | Method to inhibit neutrophil recruitment to damaged tissue using myeloid-derived growth factor |
| JP2024501821A (ja) | 2020-12-23 | 2024-01-16 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 心臓組織細胞に対する特異性を有するウイルスカプシドタンパク質 |
| CN115820829B (zh) * | 2022-03-22 | 2026-04-17 | 中国人民解放军军事科学院军事医学研究院 | Mydgf在防治记忆损伤及其相关疾病中的应用 |
| CA3258215A1 (en) | 2022-06-03 | 2023-12-07 | Boehringer Ingelheim International Gmbh | RECOMBINANT EXPRESSION OF THE MYELOID-DERIVED GROWTH FACTOR |
| CN120112304A (zh) | 2022-09-08 | 2025-06-06 | 勃林格殷格翰国际有限公司 | 用于治疗心源性休克的髓源性生长因子 |
| EP4480490A1 (en) * | 2023-06-23 | 2024-12-25 | Medizinische Hochschule Hannover | Brick1 for use in treating myocardial diseases |
| WO2025073372A1 (en) | 2023-10-05 | 2025-04-10 | Boehringer Ingelheim International Gmbh | Recombinant expression of myeloid-derived growth factor |
| WO2025120204A1 (en) | 2023-12-06 | 2025-06-12 | Boehringer Ingelheim International Gmbh | Novel formulation comprising myeloid-derived growth factor |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0173552B1 (en) | 1984-08-24 | 1991-10-09 | The Upjohn Company | Recombinant dna compounds and the expression of polypeptides such as tpa |
| WO1997047358A1 (en) | 1996-06-11 | 1997-12-18 | Merck & Co., Inc. | Synthetic hepatitis c genes |
| JP2001506484A (ja) | 1996-09-13 | 2001-05-22 | 財団法人相模中央化学研究所 | 分泌シグナル配列を有するヒト蛋白質およびそれをコードするｄｎａ |
| AU4220797A (en) * | 1996-09-13 | 1998-04-02 | Protegene Inc. | Human proteins having secretory signal sequences and DNAs encoding these prot eins |
| EP1578367A4 (en) | 2002-11-01 | 2012-05-02 | Genentech Inc | COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNE DISEASES |
| WO2004069173A2 (en) | 2003-01-31 | 2004-08-19 | The Trustees Of The University Of Pennsylvania | Methods for modulating an inflammatory response |
| US20080004232A1 (en) | 2006-05-09 | 2008-01-03 | John Wilkins | Characterization of c19orf10, a Novel Synovial Protein |
| EP2130547A1 (en) | 2008-06-06 | 2009-12-09 | Giuliani International Limited | IL-25 for use in the treatment of inflammatory diseases |
| EP3747457A3 (en) | 2013-01-17 | 2021-03-03 | Medizinische Hochschule Hannover | Factor 1 protein, factor 2 protein and inhibitors thereof for use in treating or preventing diseases |
| KR20250133994A (ko) * | 2018-05-09 | 2025-09-09 | 케로스 테라퓨틱스, 인크. | 액티빈 수용체 유형 iia 변이체 및 그의 사용 방법 |
| WO2020176732A1 (en) * | 2019-02-27 | 2020-09-03 | Icahn School Of Medicine At Mount Sinai | TREATMENT OF PULMONARY FIBROSIS WITH SERCA2a GENE THERAPY |
-
2021
- 2021-01-19 MX MX2022008727A patent/MX2022008727A/es unknown
- 2021-01-19 EP EP21701283.0A patent/EP4093750A1/en active Pending
- 2021-01-19 TW TW110102010A patent/TW202142254A/zh unknown
- 2021-01-19 CA CA3164500A patent/CA3164500A1/en active Pending
- 2021-01-19 BR BR112022014272A patent/BR112022014272A2/pt unknown
- 2021-01-19 CA CA3223879A patent/CA3223879A1/en active Pending
- 2021-01-19 CN CN202180022864.1A patent/CN115698048A/zh active Pending
- 2021-01-19 WO PCT/EP2021/051079 patent/WO2021148411A1/en not_active Ceased
- 2021-01-19 US US17/759,056 patent/US20230059560A1/en active Pending
- 2021-01-19 KR KR1020227027546A patent/KR20220131262A/ko active Pending
- 2021-01-19 AU AU2021211874A patent/AU2021211874A1/en active Pending
- 2021-01-19 PH PH1/2022/551792A patent/PH12022551792A1/en unknown
- 2021-01-19 JP JP2022544144A patent/JP7777532B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023511358A (ja) | 2023-03-17 |
| TW202142254A (zh) | 2021-11-16 |
| EP4093750A1 (en) | 2022-11-30 |
| CA3164500A1 (en) | 2021-07-29 |
| WO2021148411A1 (en) | 2021-07-29 |
| MX2022008727A (es) | 2022-10-07 |
| JP7777532B2 (ja) | 2025-11-28 |
| AU2021211874A1 (en) | 2022-08-25 |
| CA3223879A1 (en) | 2021-07-29 |
| CN115698048A (zh) | 2023-02-03 |
| PH12022551792A1 (en) | 2023-09-18 |
| KR20220131262A (ko) | 2022-09-27 |
| US20230059560A1 (en) | 2023-02-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022014272A2 (pt) | Fator de crescimento derivado de mieloide para uso no tratamento ou prevenção de fibrose, hipertrofia ou insuficiência cardíaca | |
| McCain et al. | Matrix elasticity regulates the optimal cardiac myocyte shape for contractility | |
| PE20240728A1 (es) | Sistemas de represores de casx disenados por ingenieria genetica | |
| Gregorich et al. | Top-down targeted proteomics reveals decrease in myosin regulatory light-chain phosphorylation that contributes to sarcopenic muscle dysfunction | |
| BR112015022971A2 (pt) | métodos de fabricação para controlar o teor de lisina c-terminal, galactose e ácido siálico em proteínas recombinantes | |
| BR112017008108A2 (pt) | incorporação de aminoácidos não naturais em proteínas | |
| MX2021014952A (es) | Molecula de union especifica para cd73 y uso de la molecula de union. | |
| MX2009007308A (es) | Plantas que tienen rasgos relacionados con el rendimiento mejorado y/o resistencia al estres abiotico aumentada y un metodo para obtener las mismas. | |
| BR112019001108A2 (pt) | usos de vesículas extracelulares compreendendo uma proteína de fusão tendo capacidade de ligação a fc | |
| BR112019011860A2 (pt) | proteína de fusão insulina-fc, sequência de ácido nucleico recombinante que codifica a mesma, vetor, célula eucariótica modificada, kit e método para tratar ou prevenir o diabetes autoimune | |
| BR112023005674A2 (pt) | Construtos anti-cd93 e usos dos mesmos | |
| AR107463A1 (es) | Gen de bacillus thuringiensis con actividad contra el orden lepidoptera | |
| BRPI0713000A8 (pt) | Proteína de ligação multiespecífica de cadeia simples, composição farmacêutica e uso da referida proteína de ligação multiespecífica de cadeia simples | |
| BR112018003753A2 (pt) | bifidobacterium longum | |
| BR112022008075A2 (pt) | Métodos de seqüênciamento de proteínas de célula única e de ácido nucleico | |
| BR112017025929A2 (pt) | genes pesticidas e métodos de uso | |
| CL2017000200A1 (es) | Célula huésped mejorada para producir proteinas | |
| BR112022012327A2 (pt) | Anticorpos ou fragmentos dos mesmos, ácido nucleico, vetor e célula hospedeira | |
| AR094114A1 (es) | Proteinas resistentes a herbicidas, genes que las codifican y sus usos | |
| CL2025002422A1 (es) | Métodos y composiciones para la administración de sistemas de vector dual otoferlin. | |
| BR112015026707A2 (pt) | Proteína ppr, e, complexo | |
| BR112022019571A2 (pt) | Método para editar um ácido ribonucleico alvo, domínio dyw, proteína dyw, composição para editar ácido ribonucleico em uma célula eucariótica, ácido nucleico, vetor, e, célula | |
| Rodríguez-Hernández et al. | The identification of a VDAC-like protein involved in the interaction of Babesia bigemina sexual stages with Rhipicephalus microplus midgut cells | |
| DOP2024000253A (es) | Expresión recombinante del factor de crecimiento derivado de mieloides | |
| BR112013025975A2 (pt) | proteína de fusão anticancerígena |